Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPDGlobeNewsWire • 03/31/20
Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPDGlobeNewsWire • 03/31/20
Verona Pharma plc (VRNA) CEO David Zaccardelli on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/28/20
Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory ResearchGlobeNewsWire • 02/14/20
Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium TherapyGlobeNewsWire • 01/13/20
Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor RelationsGlobeNewsWire • 01/07/20
Holding(s) in Company TR-1: Standard form for notification of major holdings.GlobeNewsWire • 11/28/19
Verona Pharma plc (VRNA) CEO Jan-Anders Karlsson on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/10/19
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019GlobeNewsWire • 11/05/19
Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPDGlobeNewsWire • 10/17/19
Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019GlobeNewsWire • 10/15/19
Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019GlobeNewsWire • 09/19/19
Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment ConferenceGlobeNewsWire • 09/03/19
Verona Pharma plc (VRNA) CEO Jan-Anders Karlsson on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/13/19